Edgewise Therapeutics Inc (EWTX) - Net Assets
Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) has net assets worth $493.20 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($518.52 Million) and total liabilities ($25.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Edgewise Therapeutics Inc (EWTX) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $493.20 Million |
| % of Total Assets | 95.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | 90.34% |
| 10-Year Change | N/A |
| Growth Volatility | 18.97 |
Edgewise Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Edgewise Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore EWTX current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Edgewise Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Edgewise Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see Edgewise Therapeutics Inc (EWTX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $522.26 Million | +13.73% |
| 2024-12-31 | $459.22 Million | +44.03% |
| 2023-12-31 | $318.83 Million | -8.04% |
| 2022-12-31 | $346.72 Million | +26.36% |
| 2021-12-31 | $274.38 Million | +921.01% |
| 2020-12-31 | $-33.42 Million | -98.30% |
| 2019-12-31 | $-16.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Edgewise Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52934700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.00% |
| Other Comprehensive Income | $677.00K | 0.13% |
| Other Components | $1.07 Billion | 204.49% |
| Total Equity | $522.26 Million | 100.00% |
Edgewise Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Edgewise Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanxiang Advanced Materials
SHG:603663
|
$3.61 Billion |
|
Holmen AB (publ)
ST:HOLM-B
|
$3.61 Billion |
|
Bumi Resources Tbk
JK:BUMI
|
$3.61 Billion |
|
Baoding Tianwei Baobian Electric Co Ltd
SHG:600550
|
$3.61 Billion |
|
Brady Corporation
NYSE:BRC
|
$3.61 Billion |
|
Grinm Advanced Materials Co Ltd
SHG:600206
|
$3.60 Billion |
|
Chongqing Brewery Co Ltd
SHG:600132
|
$3.60 Billion |
|
Advanced Technology & Materials Co Ltd
SHE:000969
|
$3.60 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Edgewise Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 459,216,000 to 522,257,000, a change of 63,041,000 (13.7%).
- Net loss of 167,795,000 reduced equity.
- New share issuances of 187,362,000 increased equity.
- Other comprehensive income increased equity by 257,000.
- Other factors increased equity by 43,217,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-167.79 Million | -32.13% |
| Share Issuances | $187.36 Million | +35.88% |
| Other Comprehensive Income | $257.00K | +0.05% |
| Other Changes | $43.22 Million | +8.28% |
| Total Change | $- | 13.73% |
Book Value vs Market Value Analysis
This analysis compares Edgewise Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.34 | $33.56 | x |
| 2020-12-31 | $-0.68 | $33.56 | x |
| 2021-12-31 | $5.54 | $33.56 | x |
| 2022-12-31 | $6.47 | $33.56 | x |
| 2023-12-31 | $5.00 | $33.56 | x |
| 2024-12-31 | $4.97 | $33.56 | x |
| 2025-12-31 | $5.07 | $33.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Edgewise Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-32.13%) is below the historical average (-16.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.80 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.71 Million |
| 2021 | -15.36% | 0.00% | 0.00x | 1.04x | $-69.58 Million |
| 2022 | -4.44% | 0.00% | 0.00x | 1.06x | $-50.07 Million |
| 2023 | -31.42% | 0.00% | 0.00x | 1.07x | $-132.05 Million |
| 2024 | -29.14% | 0.00% | 0.00x | 1.06x | $-179.73 Million |
| 2025 | -32.13% | 0.00% | 0.00x | 1.06x | $-220.02 Million |
Industry Comparison
This section compares Edgewise Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,374,900
- Average return on equity (ROE) among peers: -53.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Edgewise Therapeutics Inc (EWTX) | $493.20 Million | 0.00% | 0.05x | $3.61 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $91.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $312.29 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $174.79 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $823.18 Million |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $540.89 Million | -31.04% | 0.29x | $3.64 Billion |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more